Tech Company Financing Transactions

Ascenta Therapeutics Funding Round

Ascenta Therapeutics secured a $50 million Series C funding round on 4/9/2007. Investors included Perseus, Domain Associates and Enterprise Partners Venture Capital.

Transaction Overview

Company Name
Ascenta Therapeutics
Announced On
4/9/2007
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series C
Investors

Perseus (Lead Investor) (Norman Selby)

Domain Associates (Eckhard Weber)

Enterprise Partners Venture Capital (Drew Senyei)

Scale Venture Partners (Lou Bock)

Sofinnova Ventures (Michael Powell)

U.S. Venture Partners (Jonathon Root)

Proceeds Purpose
Proceeds from the Series C financing will be used to advance AT-101, an oral pan-Bcl-2 inhibitor, through Phase 2 clinical trials in several cancers and to advance Ascenta's pipeline programs to the clinic.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
101 Lindenwood Dr. 405
Malvern, PA 19355
USA
Phone
(610) 408-0301
Website
www.ascenta.com
Email Address
[email protected]
Overview
Ascenta Therapeutics, a clinical-stage biopharmaceutical company, focuses on the discovery and development of new medicines to treat cancer.
Profile
Ascenta Therapeutics LinkedIn Company Profile
Social Media
Ascenta Therapeutics Company Twitter Account
Company News
Ascenta Therapeutics News
Facebook
Ascenta Therapeutics on Facebook
YouTube
Ascenta Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Mel Sorensen
  Mel Sorensen LinkedIn Profile  Mel Sorensen Twitter Account  Mel Sorensen News  Mel Sorensen on Facebook
Chief Financial Officer
Joel Sussman
  Joel Sussman LinkedIn Profile  Joel Sussman Twitter Account  Joel Sussman News  Joel Sussman on Facebook
VP - Bus. Development
Brian Wood
  Brian Wood LinkedIn Profile  Brian Wood Twitter Account  Brian Wood News  Brian Wood on Facebook
VP - Operations
Jeffrey Brill
  Jeffrey Brill LinkedIn Profile  Jeffrey Brill Twitter Account  Jeffrey Brill News  Jeffrey Brill on Facebook

 

 

Browse more venture capital transactions:

Prev: 4/7/2007: Lithium Technologies venture capital transaction
Next: 4/9/2007: Kalido venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on tech company VC transactions. VC investment data records on this site are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.